Boosting a natural change in alpha-synuclein lowers its ability to clump
A natural chemical modification — called O-GlcNAc — that occurs in specific building blocks of the alpha-synuclein protein can lessen…
Articles by Patricia Inácio, PhD
VUMC now part of CurePSP, focused on atypical parkinsonism
The department of neurology at Vanderbilt University Medical Center (VUMC) is now part of the CurePSP Center of Care…
Topline buntanetap trial data in early-stage Parkinson’s due ‘soon’
Topline data from a Phase 3 clinical trial of buntanetap in early-stage Parkinson’s disease patients is expected soon, according…
Small molecules aim to detangle and stop protein clumps of Parkinson’s
Scientists at Purdue University are advancing in lab studies multiple small molecule compounds aiming to prevent the protein aggregation associated…
Brain organoids derived from patients taken to space station
3D “mini-brains,” or brain organoids, derived from people with Parkinson’s disease and primary progressive multiple sclerosis (MS) are…
Coya adds Parkinson’s as disease target for ALS therapy COYA 302
Coya Therapeutics is expanding the pipeline for its COYA 302 immunotherapy, adding two neurodegenerative disorders — frontotemporal dementia (FTD)…
Possible Parkinson’s treatment seen in template to make alpha-synuclein
Scientists have developed a molecule that promotes the clearance of toxic clumps of the alpha-synuclein protein — a hallmark of…
FDA favors Phase 2 trial of oral ZYIL1 in Parkinson’s patients
The U.S. Food and Drug Administration (FDA) has given Zydus Lifesciences a green light to conduct a Phase 2 trial…
Neurocrine opening two Phase 1 trials in oral Parkinson’s therapies
Neurocrine Biosciences is opening two Phase 1 clinical trials in healthy adults to test two oral candidate muscarinic…
‘Someone like them’: Black patients meet as support group
Members of the Support Group for Black Patients with Parkinson’s Disease took part in the Parkinson Council’s Walk to…